Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Angina IV: Management01:26

Angina IV: Management

366
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
366
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.6K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

815
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
815
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

433
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
433

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Effect of Intravenous Administration of Alprostadil on Circulating Microvesicles in Patients with Chronic Limb-Threatening Ischemia (CLTI): A Preliminary Study.

Journal of clinical medicine·2026
Same author

Determinants of In-Stent Restenosis in ST-Elevation Myocardial Infarction: Insights from a Single-Center Retrospective Analysis.

Medicina (Kaunas, Lithuania)·2026
Same author

MicroRNA profiles in multiple sclerosis: A review of the literature.

Journal of neuroimmunology·2026
Same author

Cardiovascular Involvement in Systemic Lupus Erythematosus: Focus on Arrhythmias.

Diagnostics (Basel, Switzerland)·2026
Same author

Post-COVID-19 Muscle Weakness and Recovery Patterns After Mild-to-Moderate Infection: A Retrospective Analysis of a Structured Rehabilitation Program Using the MRC Scale.

Healthcare (Basel, Switzerland)·2026
Same author

Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams.

Life (Basel, Switzerland)·2025

相关实验视频

Updated: Feb 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K

静脉静脉复原病理生理学和危险因素:综合性审查

Alice Elena Munteanu1,2, Alexandru Andrei Badea3, Alexandru Mihai Popescu3

  • 1Department of Cardiology, 'Carol Davila' Central Military Emergency University Hospital, 010825 Bucharest, Romania.

Medicina (Kaunas, Lithuania)
|February 27, 2026
PubMed
概括

支架内静止症 (ISR) 是支架后的一个复杂问题,由新极端增生和新动脉样硬化驱动. 了解其机制和风险因素是有效的患者管理和预防复发性缺血的关键.

关键词:
急性冠状动脉综合征是什么裸金属支架是一种裸金属支架.药物释放的支架可以释放药物.内皮质功能障碍 在内皮质功能障碍在内置支架的新动脉样硬化症.在静脉支架内恢复缩.新极端的增生过度增生.通过皮肤进行冠状动脉干预.目标病变的重血管化血管光滑肌肉细胞的细胞.

更多相关视频

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.4K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.9K

相关实验视频

Last Updated: Feb 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.4K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.9K

科学领域:

  • 心血管医学 心血管医学
  • 干预心脏病学 干预心脏病学
  • 生物医学工程 生物医学工程

背景情况:

  • 静脉静脉复缩 (ISR) 是复发性缺血和重复血管化的重要原因,尽管静脉静脉技术取得了进步.
  • 虽然药物排泄支架 (DES) 与裸金属支架 (BMS) 相比,降低了复缩率,但ISR仍然是一个长期关注的问题,其结果比皮肤冠状动脉干预 (PCI) 对新发性病变更差.

研究的目的:

  • 审查当前关于生物学的证据,风险因素和静脉静脉复缩的管理.
  • 支持ISR风险分层,预防策略和个性化治疗方法.

主要方法:

  • 综合目前关于ISR生物学和风险因素的证据.
  • 对ISR的机制性见解的审查,包括新极端增生和新动脉样硬化.
  • 讨论临床表现,患者水平和病变/程序风险决定因素.

主要成果:

  • ISR是一个取决于时间的,异质的过程,涉及早期的新极度增生和晚些时候的新动脉样硬化.
  • 患者的关键风险因素包括糖尿病,慢性病,脂质不良,高血压和吸烟.
  • 损伤/手术因素包括小血管,复杂的损伤,多种支架和低于最佳的扩张.
  • 血管内成像 (OCT/IVUS) 对ISR机制的表型和指导治疗至关重要.

结论:

  • ISR需要迅速识别和机制知情管理,通常呈现为急性冠状动脉综合征 (ACS).
  • 基于患者和程序因素的风险分层是至关重要的.
  • 血管内成像有助于定制ISR的预防和治疗策略.